Suppression of immunoglobulin production by a novel dihydroorotate dehydrogenase inhibitor, S-2678.

@article{Deguchi2008SuppressionOI,
  title={Suppression of immunoglobulin production by a novel dihydroorotate dehydrogenase inhibitor, S-2678.},
  author={Masashi Deguchi and Junji Kishino and Maki Hattori and Yoko Furue and Mina Yamamoto and Izumi Mochizuki and Motofumi Iguchi and Yosuke Hirano and Kanji Hojou and Morio Nagira and Yoshinori Nishitani and Kenichi Okazaki and Kiyoshi Yasui and Akinori Arimura},
  journal={European journal of pharmacology},
  year={2008},
  volume={601 1-3},
  pages={
          163-70
        }
}
View on PubMed
doi.org
5 Citations
Background Citations
1

Figures and Tables from this paper

5 Citations

Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy.
TLDR
Recent studies to exploit the fourth enzyme in the de novo pyrimidine biosynthetic pathway of P. falciparum, dihydroorotate dehydrogenase, as a new target for drug discovery provide strong evidence that PfDHODH is a validated target for the identification of new antimalarial chemotherapy.
RSC_IB_C2IB20204B 1..21
TLDR
The overall data suggest that the medicinal herbs function by indirectly suppressing the virus proliferation via regulating the immune systems in hosts, and also, by directly inhibiting virus proliferation through targeting viral proteins essential for the viral life cycle.
Systems pharmacology uncovers Janus functions of botanical drugs: activation of host defense system and inhibition of influenza virus replication
  • Xia Wang, Xue Xu, Ling Yang
  • Biology, Medicine
    Integrative biology : quantitative biosciences from nano to macro
  • 2013
TLDR
The overall data suggest that the medicinal herbs function by indirectly suppressing the virus proliferation via regulating the immune systems in hosts, and also, by directly inhibiting virus proliferation through targeting viral proteins essential for the viral life cycle.
Discovery of novel inhibitors for DHODH via virtual screening and X-ray crystallographic structures.
Class 1 Oxidoreductases

References

SHOWING 1-10 OF 22 REFERENCES
Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide.
TLDR
DHO-DH inhibition by A77 1726 and its analogues is responsible for the anti-proliferative effects in vitro of the compounds on human cells and is likely to be responsible for some of its effects in vivo.
Leflunomide Inhibits Pyrimidine de Novo Synthesis in Mitogen-stimulated T-lymphocytes from Healthy Humans*
TLDR
It is proved conclusively that the prime target in proliferating human T-lymphocytes is pyrimidine biosynthesis at the level of dihydroorotic-acid dehydrogenase, and de novo purine synthesis occurred secondary to inhibition of proliferation since this was reversed by uridine rescue, except at 100 μm Leflunomide.
In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: mechanisms of action.
The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.
TLDR
The results support the hypothesis that the in vitro effects of leflunomide on T-lymphocytes are due to inhibition of de novo pyrimidine synthesis, and inhibition of dihydroorotate dehydrogenase.
Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production.
TLDR
The addition of uridine restored proliferation and IgM secretion to leflunomide-treated LPS-stimulated B cells, but it did not completely restore secretion of IgG Ab.
Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression.
TLDR
It is demonstrated that treatment of a human T cell line with leflunomide blocks TNF-mediated NF-kappa B activation in a dose- and time-dependent manner, with maximum inhibition at 5-10 microM, and this provides the molecular basis for its anti-inflammatory and immunosuppressive effects.
Regulation of B cell function by the immunosuppressive agent leflunomide.
TLDR
It is demonstrated that leflunomide functions to inhibit murine B cell antibody production by directly acting on the B cell, thereby inhibiting B cell proliferation and cell cycle progression.
Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.
Discovery of activation-induced cytidine deaminase, the engraver of antibody memory.
Class Switch Recombination and Hypermutation Require Activation-Induced Cytidine Deaminase (AID), a Potential RNA Editing Enzyme
...
...